secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arbutus Biopharma Corp (ABUS)
CIK:        0001447028
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0001171843-23-006951
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arbutus and Barinthus report preliminary Phase 2a data: imdusiran + VTP-300 sustains low HBsAg levels in cHBV
--------------------------------------------------------------------------------

- Preliminary data from AB-729-202 trial: 97% of imdusiran-treated pts had HBsAg <100 IU/mL at first VTP-300 dose.
- Mean HBsAg reduction of -1.86 log10 after 24 weeks of imdusiran; all VTP-300 patients maintained <100 IU/mL through week 48.
- 60% of VTP-300 patients had HBsAg <10 IU/mL through week 48; all qualified to stop NA therapy.
- HBV-specific T cell IFN-γ production enhanced vs placebo; no serious AEs, Grade 3/4 AEs, or discontinuations.
- Updated corporate presentation posted on company website with additional pipeline details.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447028/000117184323006951/0001171843-23-006951-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447028/000117184323006951/f8k_110923.htm
  HTML page:      https://secwatch.observer/filing/0001171843-23-006951

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer